Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro  by Lee, Robert J & Low, Philip S
ELSEVIER Biochimica et Biophysica Acta 1233 (1995) 134-144 
Biochi~& et Biophysica ~ta 
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin 
in vitro 
Robert J .  Lee, Philip S. Low * 
Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA 
Received 15 July 1994; accepted 25 September 1994 
Abstract 
Receptors for the vitamin folic acid are frequently overexpressed onepithelial cancer ceils. To examine whether this overexpression 
might be exploited to specifically deliver liposome-encapsulated drug molecules in vitro, folate-targeted liposomes were prepared by 
incorporating 0.1 mol% of a folate-polyethyleneglycol-distearoylphosphatidylethanolamine (folate-PEG-DSPE) construct into the lipid 
bilayer, and were loaded with doxorubicin (DOX), an anti-cancer drug. Uptake of folate-PEG-liposomal DOX by KB cells was 45-fold 
higher than that of non-targeted liposomal DOX, and 1.6-times higher than that of free DOX, while the cytotoxicity was 86 and 2.7-times 
higher, respectively. Folate-targeting is fully compatible with PEG-coating of the liposomes, ince incorporation of 4 mol% PEG2000- 
DSPE does not reduce the uptake or cytotoxicity of folate-PEG-liposomal DOX. Uptake of folate-PEG-liposomes was inhibited by 1 mM 
free folic acid but was unaffected by physiological concentrations of folate. In HeLa/WI38 co-cultures, folate-PEG-liposomes 
encapsulating calcein, a fluorescent dye, were found to be almost exclusively internalized by the HeLa cells which overexpress the folate 
receptors. We suggest that folate targeting constitutes a possible mechanism for improving the specificity of PEG-coated liposomes for 
cancer cells. 
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1. Introduction 
Although doxorubicin (DOX) is one of the most widely 
used anticancer agents, its clinical application is still lim- 
ited by its deleterious side effects, including myelosuppres- 
sion, gastrointestinal toxicity, and especially cardiotoxicity 
[1]. To avoid these complications, the use of liposomes as 
carriers for DOX has been recently explored in both 
animal and human trials [2-9]. In general, liposomal DOX 
exhibits enhanced antitumor activity as well as improved 
therapeutic ndex. The advantages of liposomal DOX over 
free DOX derive largely from the former's prolonged 
Abbreviations: PEG, polyethyleneglycol; PEG-bis-amine, polyoxyeth- 
ylene-bis-amine; PBS, phosphate-buffered saline (136.9 mM NaC1, 2.68 
mM KC1, 8.1 mM Na2HPO4, 1.47 mM KH2PO+, pH 7.4); DOX, 
doxorubicin; M'IT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; IC50, drug concentration giving 50% cell killing; PEG2000- 
DSPE, polyethyleneglycol (M.W. = 2000) derivatized istearoylphos- 
phatidylethanolamine. 
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systemic irculation, reduced peak levels, and sustained 
release of the drug into the blood stream [5]. Liposomes 
also have a tendency to extravasate and preferentially 
accumulate in tumor tissues with leaky endothelia nd 
reduced lymphatic drainage [6]. 
The attractiveness of liposomes as drug carriers was 
further enhanced by the recent introduction of long-cir- 
culating liposomes coated with polyethyleneglycol (PEG). 
By protecting the liposome surface from non-specific op- 
sonization by certain plasma components, the PEG coating 
inhibits the recognition of the liposomes by phagocytes of 
the reticuloendothelial system [2,10-18]. Unfortunately, 
recent studies also indicate that steric hindrance introduced 
by the PEG-coating on the liposome surface can inhibit 
ligand-mediated targeting of the liposome when the target- 
ing ligand, e.g., an antibody, is directly conjugated to the 
lipid bilayer [19-21]. We found that liposomes can be 
efficiently targeted to receptor-bearing tumor cells when 
conjugated to folate via a long PEG-spacer [22]. Recent 
studies in other laboratories also indicate that PEG-coated 
liposomes attached to an antibody via a long PEG spacer 
show both effective target binding and prolonged circula- 
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tion times [23,24]. Therefore, it is likely that similar 
advantages will be shared by PEG-coated liposomes at- 
tached to folate via a PEG spacer [22]. 
Folate binding protein, a glycosylphosphatidylinositol- 
anchored cell surface receptor for the vitamin folic acid, 
has recently been shown to be vastly overexpressed in a 
wide variety of human tumors, especially ovarian carcino- 
mas [25-31]. This observation has raised the possibility of 
using folate-PEG-liposomes to specifically deliver anti- 
cancer drugs to these tumors, since similar studies using 
antibody as the targeting ligand gave promising results in 
vitro as well as in vivo [32-36]. As an initial investigation 
of this potential application, we have examined the uptake 
and cytotoxicity of folate-targeted liposomes in two lines 
of cultured tumor cells overexpressing the folate receptor, 
KB and HeLa, as well as co-cultured HeLa and WI38 cells 
(a non-transformed line). We report here that encapsulation 
within folate-PEG-liposomes increases both the potency 
and specificity of DOX. The intracellular fate of folate- 
PEG-liposomal DOX and the potential for folate-PEG- 
liposomes as in vivo drug carriers are discussed. 
2. Mater ia l s  and  methods  
2.1. Materials 
DOX was purchased from Calbiochem. PEG2000-DSPE 
was acquired from Avanti Polar Lipids. Distearoylphos- 
phatidylethanolamine (DSPE), distearoylphosphatidyl- 
choline (DSPC), folic acid, polyoxyethylene-bis-amine 
(PEG-bis-amine, M.W. --~ 3350), 3-(4,5-dimethylthiazol-2- 
yl)-2,5-diphenyltetrazolium bromide (MTT), and non-en- 
zymatic cell-dislodging solution were purchased from 
Sigma. 
2.2. Methods 
Cell Culture. KB cells, a human nasopharyngeal epider- 
mal carcinoma cell line, HeLa cells, a human cervical 
carcinoma cell line, and WI38 cells, a human lung fibrob- 
last primary cell line were kindly provided by the Purdue 
Cancer Center. All cells were maintained in a medium 
containing physiological concentrations of folate, i.e., min- 
imum essential medium minus the folic acid additives and 
supplemented with 10% heat-inactivated fetal calf serum 
[37]. The cells were grown at 37°C in a humidified atmo- 
sphere containing 5% CO 2. The folate content of the fetal 
calf serum supplement brings the folate concentration of
the medium to a near physiological value for human 
serum. 
Synthesis of folate-PEG-DSPE. The synthesis of the 
folate-PEG-DSPE construct is illustrated in Fig. 1. 
Folate-PEG-NH 2 was synthesized by reacting 500 mg 
polyoxyethylene-bis-amine with an equimolar quantity of 
folic acid in 5 ml dimethylsulfoxide containing one molar 
equivalent of dicyclohexylcarbodiimide and 10 txl pyri- 
dine. The reaction mixture was stirred overnight in the 
dark at room temperature. At this point, 10 ml water was 
added and the insoluble by-product, dicyclohexylurea, was 
removed by centrifugation. The supernatant was then dia- 
lyzed against 5 mM NaHCO 3 buffer (pH 9.0) and then 
against deionized water to remove the dimethylsulfoxide 
and unreacted folic acid in the mixture. The trace amount 
of unreacted polyoxyethylene-bis-amine was then removed 
by batch-adsorption with 5 g of cellulose phosphate 
cation-exchange resin pre-washed with excess 5 mM phos- 
phate buffer (pH 7.0). Although not necessary, the trace 
amount of PEG-bis-folate may be removed by anion-ex- 
change chromatography on a DEAE-trisacryl Sepharose 
column. Folate-PEG-amine can be easily eluted with 10 
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Fig. ]. Synthesis of folate-PEG-DSPE. See text for details. 
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mM NH4HCO 3 (pH 8.0). The product folate-PEG-NH 2 
was then lyophilized and analyzed for folate content by 
absorbance at 363 nm and -NH 2 content by the ninhydrin 
assay. The ratio of folate to free -NH 2 groups in this 
product was --~ 1. 
N-Succinyl-DSPE was synthesized by reacting overnight 
1.1 molar equivalent of succinic anhydride with 100 mg 
DSPE in 5 ml chloroform containing 10 /xl pyridine. The 
product was precipitated with cold acetone and verified by 
thin-layer chromatography. N-Succinyl-DSPE was re-dis- 
solved in chloroform and its carboxyl group was activated 
by reacting with one molar equivalent of dicyclohexyl- 
carbodiimide for 4 h at room temperature. An equimolar 
amount of the above synthesized folate-PEG-NH 2 dis- 
solved in chloroform was then added. After overnight 
stirring at room temperature, the solvent was removed 
from the reaction mixture, and the lipid pellet containing 
the folate-PEG-DSPE conjugate was washed twice with 
cold acetone, redissolved in chloroform, and stored at 
-20°C. The formation of folate-PEG-DSPE was con- 
firmed by reverse-phase high-pressure liquid chromatog- 
raphy. 
Liposome preparation. Liposomes of the following 
compositions were used in this study: (a) folate-PEG-lipo- 
somes composed of DSPC/cholesterol/folate-PEG-DSPE 
(56:40:0.1), (b) folate-PEG-liposomes with 4% PEG 
(M.W.  = 2000)  coat ing  composed o f  
DSPC/cholesterol/PEG2000-DSPE/folate-PEG-DSPE 
(56:40:4:0.1), (c) control liposomes not targeted with fo- 
late composed of DSPC/cholesterol (56:40), and d) con- 
trol liposomes coated with 4% PEG composed of 
DSPC/cholesterol/PEG2000-DSPE (56:40:4). 
Liposomes were prepared by a polycarbonate mem- 
brane extrusion method and were loaded with DOX using 
a transmembrane pH gradient based on a method escribed 
previously [9,35]. Briefly, 100 mg lipid mixture was dis- 
solved in chloroform and dried to a thin film in a round- 
bottom flask on a rotary evaporator under reduced pres- 
sure. The dried lipid mixture was then rehydrated in 2 ml 
of the low-pH 'trapping' buffer (400 mM citrate, 5 mM 
phosphate, pH 4.0) by vortexing. The resulting suspension 
of multilamellar vesicles was then subjected to five cycles 
of freezing and thawing, briefly sonicated, extruded five 
times through a 100 nm pore size polycarbonate mem- 
brane, and passed through a Sepharose CL-4B (Pharmacia) 
gel-filtration column (10 cm × 1.5 cm) pre-equilibrated in 
PBS. The opaque liposome fractions eluted in the void 
volume. The liposome suspension was then warmed to 
60°C in a water bath, and added to 10 mg solid DOX. The 
mixture was incubated at 60°C for another 15 min with 
intermittent vortexing and then passed through a Sepharose 
CL-4B column to separate folate-PEG-liposomal DOX 
from unencapsulated free DOX. The DOX concentration in 
the fractions collected was monitored by absorbance at475 
nm [9]. Approx. 95% of the DOX eluted with the liposome 
fractions. The DOX-loaded liposomes, with a drug/lipid 
ratio of 0.1:1 (wt/wt), were then sterilized by filtering 
through a 0.2 /xm cellulose acetate filter (Coming) and 
stored at 4°C. All liposome samples were used within two 
weeks of preparation during which period no significant 
leakage of doxorubicin from the liposomes was detected 
by gel filtration. The size distribution of the various lipo- 
some preparations was determined by light scattering, and 
the medium size of all liposome preparations was approx. 
130 nm in diameter. Since 0.1 mol% folate-PEG-DSPE 
was incorporated in the targeted liposomes, assuming equal 
distribution of this lipid in the two leaflets of the liposomal 
membrane, the number of folate ligands on the outer 
liposome surface for a 130 nm liposome should be = 75. 
Folate-PEG-liposomes ncapsulating calcein were pre- 
pared by the method escribed above except hat the lipids 
were hydrated in 25 mM calcein PBS solution. 
Uptake of folate-PEG-liposomal DOX by receptor- 
bearing tumor cells. KB or HeLa cells were transferred to 
33 mm culture dishes at 5.105 cells per dish 24 h prior to 
the assay. The cells were then incubated for 2 h at 37°C 
with 100/zg/ml free or liposomal DOX diluted in culture 
medium. In free folate competition studies, 1 mM folic 
acid was added to the incubation medium. After washing 
four times with PBS, the cells were scraped and suspended 
in 2 ml of PBS, and solubilized in 1% Triton-X 100. The 
cell-associated DOX was then determined by DOX fluo- 
rescence at 580 nm (slit = 20 nm) with excitation at 475 
nm (slit = 20 rim) on a Perkin Elmer MPF-44A fluores- 
cence spectrophotometer. Theamount of DOX was calcu- 
lated using a pre-determined standard curve and calibrated 
with the number of cells determined by a bicinchoninic 
acid (BCA) protein assay (Pierce). 
The fraction of cells participating in receptor-mediated 
uptake of folate-PEG-liposomal DOX was evaluated by 
flow cytometry. KB cells grown to 50% confluency in 75 
cm 2 culture flasks were incubated for 2 h at 37°C with 100 
/xg/ml folate-PEG-liposomal DOX diluted in 5 ml 
medium. The cells were then washed with PBS, removed 
from the bottom of the culture flask with 3 ml non-en- 
zymatic cell-dislodging solution, and analyzed for DOX 
fluorescence on a Coulter Epics Elite Flow Cytometer 
using the 488 nm line of an air-cooled argon laser as the 
excitation source. Fluorescence from cell-associated DOX 
was detected using a 550 nm long-pass emission filter. 
To visualize the intracellular distribution of cell-associ- 
ated DOX, cells treated with DOX were examined under a 
MRC600 confocal laser-scanning fluorescence microscope 
(Bio-Rad). Images were collected in the fast-photon count- 
ing mode using the 488 nm line of a krypton-argon mixed 
gas ion laser as the excitation source. A 60 X objective 
and an iris setting of 2 mm were used. Images were 
analyzed on a Macintosh IIsi computer using the public 
domain NIH Image program (written by Wayne Rasband 
at the U.S. National Institutes of Health and available from 
the Internet by anonymous ftp from zippy.nimh.nih.gov r 
on floppy disk from NTIS, 5285 Port Royal Rd., Spring- 
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field, VA 22161, part number PB93-504868), and printed 
on a CODONICS NP-1600 Photographic Network Printer. 
Cytotoxicity assay. The cytotoxicity of liposomal and 
free DOX was determined by MTF assay (a cell viability 
assay measuring the activity of a mitochondrial enzyme 
that converts MTT, a tetrazolium salt, into a formazan 
crystal that absorbs at 570 nm) as described previously 
[36]. Briefly, KB or HeLa cells were transferred tofiat-bot- 
tomed 96-well tissue culture plates (Corning) at a density 
of 5 X 104 cells per well 24 h prior to the assay. The 
culture medium in each well was carefully replaced with 
150 /xl of medium containing serial dilutions of liposomal 
or free DOX samples (in triplicates). For free ligand 
competition studies, either 1 mM folic acid or 20 nM 
5-methyltetrahydrofolate w s added to the medium used in 
the serial dilution. After 2 h incubation at 37°C, the cells 
were washed twice with sterile PBS and incubated in fresh 
culture medium for a further 48 h. At this point, 20/~1 of 5 
mg/ml  MTF dissolved in PBS was added to each well and 
the cells were incubated for another 2 h at 37°C. The 
medium was then removed and the cells solubilized in 100 
/zl isopropanol containing 0.1 M HCI. The number of 
viable cells in each well was then determined by ab- 
sorbance at 570 nm measured on an automated plate 
reader. 
In experiments evaluating the effect of co-administered 
empty liposomes on the cytotoxicity of free DOX, free 
DOX was mixed with empty liposomes at a drug to lipid 
ratio of 1:10 (identical to the drug to lipid ratio used in 
liposomal DOX). 
Selective uptake and cytotoxicity of folate-PEG-lipo- 
somes in HeLa/WI38 co-cultures. HeLa/WI38 co-cul- 
tures were prepared by plating simultaneously a mixture of 
HeLa and WI38 cells in 33 mm culture dishes 24 h prior to 
each experiment. To demonstrate he selective uptake of 
folate-PEG-liposomes, HeLa/WI38 co-cultures were incu- 
bated with 20 ~M folate-PEG-liposomal calcein, 50 /xM 
free DOX, or 50 /zM DOX encapsulated in folate-PEG- 
liposomes diluted in PBS. After 2 h incubation at 37°C, the 
dishes were washed 4 × with 2 ml PBS to remove un- 
bound fluorophores, and then examined on an Olympus 
BH-2 phase contrast/fluorescence microscope. The cells 
were photographed in both the fluorescence (dark field) 
and the phase-contrast (bright field) modes using a 40 X 
objective. 
To evaluate the selective cytotoxicity of folate-lipo- 
somal DOX, HeLa/WI38 co-cultures were treated with 10 
/xM of folate-PEG-liposomal or non-targeted liposomal 
DOX. After 2 h incubation at 37°C, the cells were care- 
fully washed four times with 2 ml sterile PBS and incu- 
bated in fresh culture medium for another 48 h. The 
co-cultures were then examined under the microscope and 
photographed. 
3. Results 
Cellular uptake of free and liposomal DO× 
Uptake of folate-PEG-liposomal DOX by cultured KB 
and HeLa cells was compared with non-targeted liposomal 
DOX and free DOX. Folate-PEG-liposomes were prepared 
by including a newly synthesized folate-PEG-DSPE con- 
struct in the lipid bilayer and were loaded with DOX by a 
'remote-loading' procedure described in Materials and 
methods. KB and HeLa cells were then incubated for 2 h 
at 37°C with liposomal or free DOX, and cell-associated 
DOX was quantitated by DOX fluorescence. DOX release 
from the various liposome formulations during the 2 h 
incubation period was less than 2% of the total encapsu- 
lated amount. 
Uptake of folate-PEG-liposomal DOX by KB cells was 
found to be 45- and 1.6-times higher than non-targeted 
liposomal DOX and free DOX, respectively (Table 1). In 
this experiment, = 1.8-101° DOX molecules per cell 
were taken up by the KB cells treated with folate-PEG- 
liposomal DOX. The level of uptake by these cells was 
Table 1 
Comparison of cellular uptake and cytotoxicity of various DOX formulations in cultured tumor cells 
DOX formulations Cellular DOX uptake ( × 109 molecules/cell) (n = 3) IC5o (gM)  
KB HeLa KB HeLa 
Folate-PEG-liposomal DOX 
Liposomal DOX 
Folate-PEG-liposomal DOX with 4% PEG-coating 
Liposomal DOX with 4% PEG-coating 
Folate-PEG-liposomal DOX + 1 mM free folic acid 
Folate-PEG-iiposomal DOX + 20 nM 
free 5-methyltetrahydrofolate 
Free DOX 
Free DO× + empty folate-PEG-liposomes 
Free DOX + empty control iposomes 
18.4 -+0.7 9.04 -+ 0.20 0.31 0.41 
0.41 5= 0.01 0.31 -+ 0.01 26.7 25.3 
18.7 -+ 1.0 9.16 _ 0.10 0.29 0.43 
0.42 -+ 0.01 0.31 + 0.01 26.5 25.1 
5.64 _+ 0.06 2.82 _+ 0.03 1.91 1.89 
18.2 +0.8 9.14 + 0.17 0.30 0.43 
11.3 _+0.4 8.23 + 0.40 0.83 0.75 
11.7 +0.3 8.27 5= 0.38 0.81 0.76 
11.5 -+0.4 8.24 + 0.31 0.85 0.77 
To determine the cellular uptake, KB or HeLa cells were incubated with 100 /xM liposomal or free DOX, after which cell-associated DOX was 
determined by fluorescence spectroscopy. Cytotoxicity was determined using the MTF assay, as described in Materials and methods. For lipid 
compositions, ee Materials and methods. IC50, DOX concentration giving 50% cell killing 
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reduced by = 70% by 1 mM free folic acid, but was 
virtually unaffected by addition of physiological concentra- 
tions (20 nM) of 5-methyltetrahydrofolate [37]. Similar 
results were obtained in HeLa cells (Table 1) except that 
the levels of folate-PEG-liposomal DOX uptake was 
50% lower, presumably due to the smaller size and lower 
folate receptor content of these cells compared to KB cells. 
Comparison of the uptake efficiencies of folate-PEG- 
liposomal DOX with and without the additional incorpora- 
tion of 4 mol% PEG2000-DSPE in the lipid bilayer re- 
vealed that folate-mediated targeting was virtually unaf- 
fected by addition of PEG-conjugated lipids to the lipo- 
some composition. Thus, the PEG segment (M.W. = 3350) 
between the folate and the DSPE membrane anchor serves 
as an effective spacer sufficient to completely overcome 
the steric hindrance introduced by the PEG-coating of 
liposomes required for prolonged in vivo circulation. 
Histograms of KB cell-associated DOX fluorescence 
generated by flow cytometry (Fig. 2) showed only a single 
peak. This result indicates that essentially all cells in the 
flask internalized a similar concentration of the folate- 
PEG-liposomal DOX. 
The intracellular distribution of cell-associated DOX 
was examined by confocal microscopy. As shown in Fig. 
3, DOX fluorescence in cells treated with folate-PEG-lipo- 
somes was mainly distributed in endocytic vesicles, in the 
nucleus, and throughout the cytosol. It is important to 
recognize that the DOX fluorescence inside these lipo- 
somes was quenched = 85% compared to free DOX (data 
not shown) due to its highly aggregated state inside the 
liposomes. Therefore, the endosomal compartments of these 
cells may contain significantly more folate-PEG-liposomal 
DOX than indicated by their relative fluorescence intensi- 
ties. Cells treated with control liposomes, however, showed 
little fluorescence above the background. Cells treated with 
free DOX displayed a similar DOX distribution to cells 
treated with the folate-PEG-liposomal preparation, except 
the endosomal fluorescence was more intense, probably 
due to lower self-quenching. Since liposomes with the 
composition we used rarely fuse with the plasma or endo- 
somal membranes, DOX found in non-endosomal compart- 
ments must be drug released from the liposomes following 
endocytosis. This discharge of DOX from folate-PEG-lipo- 
somes is probably facilitated by the outward-directed pH 
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Fig. 2. Flow cytometry profiles of fluorescence from cell-associated DOX. KB cells were incubated with folate-PEG-liposomal DOX as described in 
Materials and methods. Upper panel, autofluorescence of untreated cells. Lower panel, KB ceils treated with folate-PEG-liposomal DOX. 
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gradient across the liposomal membrane following uptake 
into the endosomes. Unpublished data in our laboratory 
show that liposomal DOX release is greatly accelerated 
when transferred from pH 7.4 to pH 5.0, a pH value found 
in endosomal compartments of the folate endocytosis path- 
way. Similarly, when free DOX enters the cell, pH gradi- 
ent across the endosomal membrane may drive its accumu- 
lation into the acidic endosomal compartments via a simi- 
lar mechanism. However, we recognize that quantitative 
information of intracellular DOX distribution cannot be 
extrapolated merely from these fluorescence images, since 
we do not know the degree of DOX fluorescence quench- 
ing in every subcellular compartment. 
Cytotoxicity of folate-PEG-liposomal DOX 
The cytotoxicities of various DOX formulations to KB 
and HeLa cells were also compared. KB or HeLa cells 
grown in 96-well plates were exposed to serial dilutions of 
liposomal or free DOX for 2 h, and cell viability was 
determined by the MTT assay following 48 h further 
incubation, as described in Materials and methods. DOX 
concentrations leading to 50% cell-killing (IC50) were 
determined from concentration-dependent cell viability 
curves. As shown in Table 1, the IC50 of folate-PEG-lipo- 
somal DOX was 0.31 /xM and 0.41 /zM for KB and HeLa 
cells, respectively, which was 86- and 62-times lower than 
DOX in non-targeted liposomes, but only 2.7- and 1.8-times 
lower than free DOX. Empty folate-PEG-liposomes or
non-targeted liposomes at lipid concentrations 100-times 
that of the IC50 of the corresponding DOX-containing 
liposomes howed no cytotoxicity against cultured KB or 
HeLa cells. These empty liposomes also show no effects 
on the cytotoxicity of co-administered free DOX (Table 1). 
Selective uptake of folate-PEG-liposomes byHeLa cells in 
HeLa / W138 co-cultures 
WI38 cells, a non-transformed human lung cell line, 
exhibit a morphology easily distinguishable from that of 
HeLa cells, a human cervical carcinoma cell line. WI38 
cells are relatively large and have a fibroblastic appear- 
ance, while HeLa cells grown in the same culture dish are 
smaller with a round or polygonal morphology (Fig. 4). 
Furthermore, like most non-transformed cells, WI38 cells 
lack folate receptors, whereas HeLa cells, typical of many 
cancer cells, greatly overexpress the folate receptors [26- 
281. 
To determine whether folate might mediate the selective 
targeting of liposomes to HeLa cells in the presence of 
receptor negative cells, HeLa/WI38 co-cultures were in- 
cubated with folate-PEG-liposomes ncapsulating calcein, 
a membrane-impermeant d pH-insensitive fluorescent 
dye and were examined under a fluorescence microscope. 
As shown in Fig. 4, a large amount of calcein-containing 
liposomes were taken up by the HeLa cells. However, 
WI38 cells in the same field did not take up any significant 
amount of fluorescence. It was also evident hat the calcein 
fluorescence associated with the HeLa cells was present on 
the cell surface as well as in internalized endocytic vesi- 
cles. 
When an analogous tudy was conducted with folate- 
PEG-liposomal DOX, essentially the same result was ob- 
served. While free DOX was taken up by both HeLa and 
Fig. 3. Confocal images of KB cells treated for 1 h with free or liposomal DOX. Left panel, KB cells treated with folate-PEG-liposomal DOX; middle 
panel, cells treated with control liposomal DOX; right panel, cells treated with free DOX. DOX is visualized by its fluorescence using the rhodamine 
dichroic mirror set. Scale bar = 20 /xm. 
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WI38 cells in the HeLa/WI38 co-culture with similar 
efficiencies, folate-liposomal DOX was clearly prefer- 
entially taken up by the HeLa cells (Fig. 4). However, the 
difference in the levels of DOX uptake between HeLa and 
adjacent WI38 cells treated with folate-PEG-liposomal 
DOX was less dramatic than in the case with folate-lipo- 
somal calcein. This is probably due to the fact that some 
DOX may release from the folate-PEG-liposomes upon 
endocytosis and subsequently transfer to adjacent WI38 
cells by diffusion. This phenomenon may actually be 
advantageous for folate-receptor-mediated in vivo target- 
ing of anti-cancer drugs to tumors where cells over-ex- 
pressing the folate receptor can lie adjacent o receptor- 
negative cancer cells. Thus the free DOX released from the 
receptor-positive cells may facilitate the killing of the 
adjacent receptor-negative tumor cells due to the 'by- 
stander' effect. This effect is likely to be less important 
when the drug molecules being targeted are very mem- 
brane-impermeable. 
Selective cytotoxicity of liposomal doxorubicin to HeLa 
cells in HeLa / WI38 co-cultures 
To further demonstrate the specificity of folate-PEG- 
liposomes for the HeLa cell population, HeLa/WI38 co- 
Fig. 4. Selective uptake of folate-PEG-liposomal calcein or DOX by HeLa cells in HeLa/WI38 cell co-cultures. HeLa/WI38 co-cultures were treated with 
folate-PEG-liposomal c lcein, free DOX or folate-PEG-liposomal DOX and photographed in both the fluorescence (dark fields) and phase-contrast mode 
(bright fields) on a microscope asdescribed inMaterials and methods. Left, cells treated with folate-PEG-liposomal caicein; middle, cells treated with free 
DOX; right, cells treated with folate-PEG-liposomal DOX. Upper panels: micrographs taken in the fluorescence mode; lower panels: the same field viewed 
in the phase contrast mode. HeLa cells appear as small round or polygonal cells. WI38 cells are considerably larger with a dendritic or fibroblast-like 
morphology. 
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0 hr. 
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Fig. 5. Selective killing of HeLa cells in a HeLa/WI38 cell co-cultures. HeLa/WI38 cell co-cultures were treated for 1 h with 10 #M doxorubicin 
encapsulated in either folate-PEG-liposomes or non-targeted liposomes and examined under phase contrast microscope after 72 b further incubation. An 
untreated control culture is displayed in the left set of panels for comparison. 
cultures were treated with 10 /xM doxorubicin encapsu- 
lated in either folate-PEG-liposomes or non-targeted lipo- 
somes. After 1 h incubation at 37°C and washing with 
PBS, the cells were further incubated for 72 h in 2 ml fresh 
medium and examined under the microscope. As shown in 
Fig. 5, co-cultures left untreated or treated with PEG-lipo- 
some-entrapped doxorubicin were dominated by HeLa cells 
due to their faster growth. The population of WI38 cells in 
the same dishes actually diminished, probably due to un- 
successful competition for limiting growth factors and 
nutrients. However, in co-cultures treated with the same 
concentration of folate-PEG-liposome-entrapped doxoru- 
bicin, HeLa cells were completely killed, leaving only 
WI38 cells in the culture dish. The selective cytotoxicity of 
folate-PEG-liposomal DOX is likely the result of the re- 
ceptor-mediated nhanced uptake of folate-PEG-liposomes 
by the HeLa cells, as well as the HeLa cells' higher 
sensitivity to DOX. 
4. Discussion 
In this paper, we have demonstrated that the anti-neop- 
lastic drug, DOX, can be specifically targeted to a cancer 
cell line in the midst of non-transformed cells by entrap- 
ment in folate-tethered liposomes. Because such constructs 
are capable of multivalent attachments o folate receptors 
on tumor cell surfaces, competition with endogenous fo- 
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lates at physiological concentrations is not observed. Al- 
though DOX administered in liposomal formulations can 
already boast several advantages over free doxorubicin 
[2-9], the incorporation of folate-PEG-DSPE molecules 
into the lipid bilayer could conceivably improve the thera- 
peutic index of the drug still further for the treatment of 
folate-receptor-positive umors. 
Results in this study showed a strong correlation be- 
tween the cytotoxicity of DOX formulations and their 
cellular uptake efficiency. However, the fold increase in 
cytotoxicity due to folate-targeting seems to exceed the 
fold increase in cellular uptake. This is probably due to the 
enhanced release of DOX from folate-PEG-liposomes fol- 
lowing their receptor-mediated internalization into the 
acidic endosomal compartments. Another factor that may 
affect the interpretation of the discrepancy in uptake en- 
hancement and cytotoxicity enhancement is hat the uptake 
assays had to be performed at a DOX concentration much 
higher than the IC50 values. At high liposome concentra- 
tions, factors such as trace amount of DOX released from 
the liposomes, and non-specific binding and endocytosis of
the liposomes by the cells may affect the observed levels 
of cellular DOX uptake. Our results also show that while 
folate-PEG-liposomal DOX was 86-times more cytotoxic 
to KB ceils than non-targeted liposomes, it is only 2.7-times 
more potent than free DOX. The reason for the much 
higher cytotoxicity of free DOX compared with non- 
targeted liposomal DOX is probably that when the cells 
were exposed to free DOX and liposomal DOX for the 
same lengths of time, the free DOX is taken up much more 
rapidly. The situation for the in vivo delivery of DOX, 
however, is likely to be entirely different, since free DOX 
is cleared much faster from systemic irculation than is 
liposomal DOX, especially when a PEG-coating is added. 
In fact, a recent study has shown that free DOX is cleared 
450-times faster than DOX encapsulated in PEG-coated 
liposomes [6]. 
Incorporation of PEG-derivatized lipids in antibody- 
conjugated liposomes has been shown to obstruct arget- 
specific cell recognition [19-21]. In contrast, folate-PEG- 
DSPE mediated elivery of liposomes to receptor-bearing 
cells was fully compatible with the inclusion of 4 mole % 
PEG-conjugated lipid. Although ligation of an antibody or 
peptide hormone ligand to the distal ends of liposome- 
anchored PEG molecules may correct he aforementioned 
targeting defect [23,24], antibody-derivatized liposomes 
suffer from additional disadvantages not shared by folate- 
targeted liposomes. Thus, antibodies can be antigenic and 
trigger complement deposition, leading to rapid liposome 
removal in vivo, precluding repeated administrations. Also, 
antibody-liposome conjugates may not be stable during 
lyophilization or conditions required for remote-loading 
and prolonged storage. Because antibodies and many pep- 
tide hormones are physically large, attachment of multiple 
copies of the polypeptides to a liposome can significantly 
increase its size and alter its properties. Since liposome 
size correlates inversely with its probability of extravasa- 
tion at the site of a tumor, and since particle size also 
correlates positively with frequency of capture by 
macrophages [41-45]), unnecessary enlargement of the 
liposome is undesirable. Thus, even though antibodies may 
offer a wider range of cell targeting specificities, folate 
may still be the preferred ligand for targeting tumors that 
overexpress the folate receptor [28-34]. 
Another disadvantage of exploiting polypeptide ligands 
for targeting liposomes to tumor cells lies in the difficulty 
of assembling drug, lipid, and lipid-conjugated antibodies 
efficiently into stable liposomes. Proteinaceous ligands are 
often not compatible with organic solvents, and therefore, 
have been commonly conjugated to preassembled lipo- 
somes containing lipids with activated head groups 
[35,37,46-51]. Such protocols, however, may lead to un- 
wanted side reactions uch as liposome crosslinking. The 
unused reactive head groups may also be cytotoxic or they 
may alter the properties of the liposomes. For example, the 
incorporation of maleiimidyl lipid head groups has been 
observed to interfere with the remote-loading of DOX. 
Furthermore, the site of attachment tothe antibody can not 
be precisely controlled, and consequently, the orientation 
of many proteins can be incompatible with receptor recog- 
nition. As an alternative, antibodies have been conjugated 
to activated lipids such as N-glutaryl-phosphatidylethanol- 
amine in aqueous dispersions and then they have been 
reassembled with drug and bilayer lipids into targeting 
liposomes by detergent dialysis [50,51]. This procedure, 
however, usually results in poor encapsulation efficiency 
for hydrophilic drug molecules, leading to a significant 
loss of chemotherapeutic agent. In contrast, folate-PEG- 
DSPE is synthesized before liposome assembly and can be 
employed with any liposome assembly method. Thus, re- 
verse phase evaporation, dehydration-rehydration, deter- 
gent dialysis, thin film hydration and sonication, etc., all 
represent drug encapsulation protocol that are compatible 
with the use of folate as the targeting ligand. 
Folate conjugation has also been exploited in the target- 
ing of protein toxins. While folate-toxin conjugates display 
approximately the same selectivity for killing cancer ceils 
as folate-PEG-liposomal DOX [38-40], the latter formula- 
tion may be more effective as an anti-neoplastic agent for 
several reasons. First, unlike bacterial toxins, folate-PEG- 
liposomes do not carry foreign antigens and are, therefore, 
not immunogenic. Further, liposome-encapsulated organic 
molecules, like doxorubicin, may be more stable during 
storage and circulation than proteinaceous toxins that rely 
on enzyme catalysis for toxicity. Whereas proteinaceous 
drugs must be directly or indirectly conjugated to folate, 
liposome-encapsulated drugs can be left unmodified, i.e., 
since the targeting ligand is attached to the packaging 
liposome. Further, liposome encapsulation protects its 
bioactive cargo from modification and delivers multiple 
copies of the drug at each folate receptor. In our study, 
= 1.8 • 101° molecules of DOX were delivered to each KB 
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cell when folate-PEG-liposomes were used as a carrier. 
Finally, where competition with endogenous folates is a 
concern, folate-linked liposomal formulations may be su- 
perior due to their higher affinities for the target cell 
resulting from multivalent binding, which can effectively 
outcompete any monovalent ligands in vivo. For the same 
reason, folate-PEG-liposomes are also likely to have higher 
affinity for the target cells than for soluble folate-receptors 
released from tumor tissues into circulation. 
Besides being a prominent tumor marker, folate recep- 
tors are also found in some normal human tissues such as 
the choroid plexus, the bone marrow, placenta, and the 
kidney [31]. The effects of these receptors on folate-media- 
ted drug targeting in vivo remain to be elucidated. How- 
ever, in preliminary live animal studies, uptake of radiola- 
beled folate conjugates by these normal tissues was small 
compared to xenographic tumor implants. 
In conclusion, we have identified a possible strategy for 
targeting liposomal doxorubicin to tumor cells. Where a 
tumor expresses the folate receptor and is accessible to 
circulating liposomes, the methodology should allow selec- 
tive delivery of the drug to the cancer tissue. Although the 
focus of the current studies has been on doxorubicin 
targeting, the strategy should also apply to other liposome 
encapsulated therapeutics, uch as other cytotoxic drugs, 
antisense nucleic acids, ribozymes, and imaging agents. A 
future step in the development of this technology will 
obviously require testing and optimization of the system in 
vivo. 
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